Table 5.
Biologic DMARD usea |
f (%) Total, n = 113 |
---|---|
Any biologic | 50 (44.2) |
Tocilizumab | 22 (19.5) |
Certolizumab | 5 (4.4) |
Etanercept | 13 (11.5) |
Adalimumab | 17 (15.0) |
Abatacept | 21 (18.6) |
Rituximab | 15 (13.3) |
DMARD disease-modifying antirheumatic drug, f frequency or frequency of observations
aBiologics other than the study medications (infliximab and intravenous golimumab only)